Business
BiomX Announces $3.0 Million Private Placement
Proceeds to Support the Company’s Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic AlternativesNESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity (“Private Placemen
About this update from Biomx Inc.
[{"type":"image","alt":"BiomX Inc","displaySize":"","headline":null,"caption":"BiomX Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/edc14f9a8fd6cf813763ff819e8305ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iDDZrA7bAG6OYNlatcV88w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/edc14f9a8fd6cf813763ff819e8305ec","width":300,"height":150}},"lazy":false},{"type":"text","content":"Proceeds to Support the Company’s Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic Alternatives","length":127,"tagName":"p"},{"type":"text","content":"NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity (“Private Placement”) financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement.","length":606,"tagName":"p"},{"type":"text","content":"About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Series Y Convertible Preferred Stock, with a stated value of $1,000 per share, together with warrants (collectively, the “Securities”) with an aggregate stated value of up to $3.3 million, for an aggregate purchase price of $3.0 million.","length":342,"tagName":"p"},{"type":"text","content":"Each share of Series Y Convertible Preferred Stock will accrue dividends at a rate of 15% per annum, payable quarterly, and will have a maturity of one year from the closing date. The Series Y Convertible Preferred Stock will be convertible into shares of the Company’s common stock, subject to the limitations set forth in the definitive agreements, including the receipt of stockholder approval to the extent required under NYSE American rules.","length":446,"tagName":"p"},{"type":"text","content":"In connection with the Private Placement, the Company will also issue warrants to acquire up to 3,300,000 shares of th...